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A B S T R A C T
An established lipopolysaccharide (LPS) model previously described in Warmbloods, was inconsistent in
Standardbred horses, where lameness was not detected despite the presence of synovitis. The present
study aimed to determine the dose of LPS from E. coli O55:B5 required to induce mild to moderate
lameness following middle carpal joint injection in Standardbred horses and to quantitate the induced
lameness over time, with and without anti-inflammatory pre-treatment. In a baseline trial, eight healthy,
clinically sound Standardbred horses were used in a rule-based dose-escalation design trial, starting at a
dose of 10 endotoxin units (EU). Lameness at trot was evaluated visually and quantitatively (using an
inertial-sensor system and pressure plate analysis). Synovial fluid aspirates were analysed for total
nucleated cell counts, total protein and prostaglandin E2 (PGE2). Following 2 months wash-out, the
effective LPS-dose determined in the baseline trial was used to evaluate the effect of anti-inflammatory
treatment. A mixed model for repeated measures with horse as random effect was used for analysis.
After injection of 10 EU LPS, the desired degree of lameness was observed in the baseline trial, with
maximal lameness at post-injection hour (PIH) 4, followed by a rapid decline and return to baseline by
PIH 48. No lameness was observed following pre-treatment with meloxicam. In synovial fluid, PGE2 was
significantly higher at PIH 8 and PIH 24 in the baseline trial compared with following meloxicam pre-
treatment. In conclusion, injection of the middle carpal joint with 10 EU LPS consistently induces a
transient lameness and synovitis in Standardbred horses.
© 2021 Elsevier Ltd. All rights reserved.
Introduction
Responses to an established lipopolysaccharide (LPS) model
previously described in Warmbloods have been inconsistent in
Standardbred horses. The model was previously documented by de
Grauw et al. (2009a,b). In those studies, 0.5 ng endotoxin (LPS) of
E. coli O55:B5 (L5418, Sigma-Aldrich) was injected intra-articularly,
inducing a mean lameness score of three, on a scale from zero
(sound) to five (severe lameness), at 8 h post-injection in
Warmblood horses. However, when using the same amount and
type of LPS was used to induce acute synovitis of the right middle
carpal joint in 24 Standardbred horses, the expected degree of
lameness was not observed, despite the obvious presence of
inflammation (Van de Water et al., 2017).
A literature review revealed a wide variability in the reported
timing of lameness evaluation moments post LPS infiltration. In
most studies in which the LPS model has been used, observations
have not been performed earlier than post-injection hour (PIH) 6–8
(Palmer and Bertone, 1994; Khumsap et al., 2003; Ishihara et al.,
2005; Kay et al., 2008; de Grauw et al., 2009a,b; Pearson et al.,* Corresponding author.
E-mail addresses: Eline.VandeWater@UGent.be, eline@dapequinox.be
Contents lists available at ScienceDirect
The Veterinary Journal
journa l homepage: www.e l sev ier .com/ locate / tv j l(E. Van de Water).
1 Current address: Equinox Equine Hospital, Vekemans 10, 2460 Kasterlee,
Belgium.
http://dx.doi.org/10.1016/j.tvjl.2021.105626
1090-0233/© 2021 Elsevier Ltd. All rights reserved.2011; Van Loon et al., 2013; de Grauw et al., 2014; Williams et al.,
2016; Cokelaere et al., 2018) or the specific timing of peak lameness
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erformed at earlier time points, the lameness peak has generally
een observed at PIH 4 (Lindegaard et al., 2010; Van Loon et al.,
010; Ross et al., 2012; Van Loon et al., 2012; Andreassen et al.,
017). In the study by Lindegaard et al. (2010) horses were treated
ith morphine at PIH 4, potentially masking a further increase in
ameness. In one of the studies evaluating lameness earlier than
IH 6–8, peak lameness was only observed at PIH 12–24 (Lucia
t al., 2013). Peak lameness has also been reported to extend from
IH 3 to 8 (Carregaro et al., 2014).
Furthermore, large variations in dosages for the induction of
ynovitis and lameness with LPS have been used, ranging from
.125 ng to 5000 ng of the same serotype of E. coli (O55:B5; Palmer
nd Bertone, 1994; Khumsap et al., 2003; Ishihara et al., 2005;
acobsen et al., 2006; Kay et al., 2008; de Grauw et al., 2009a,b;
eulyzer et al., 2009; Santos et al., 2009; Lindegaard et al., 2010;
an Loon et al., 2010; Pearson et al., 2011; Ross et al., 2012; Van
oon et al., 2012; Lucia et al., 2013; de Grauw et al., 2014;
ndreassen et al., 2017). These discrepancies in the literature raise
uestions about both the reported dosages and the evaluation
ime points of this experimental model, warranting further
nvestigation.
The first question is whether previously reported concen-
rations are accurate. Usually manufacturers of LPS solutions do
ot specify the exact concentration of the stock solution and only
rovide a qualitative indication of the concentration. In addition,
he biological activity of LPS can vary widely within the same mass
f endotoxin (Associates of Cape Cod Inc., 1997). Therefore, quite
ifferent LPS doses might be required to elicit the same biological
ffects. The use of ‘endotoxin units’ (EU) focuses on the specific
ctivity of the endotoxin and avoids the issue of different
otencies. For that reason, the use of EU has been recommended
ver the use of mass concentrations (Associates of Cape Cod, 1997).
Standardisation of the laboratory procedures for the prepara-
ion of the LPS solution are also important. Micelle formation is an
mportant feature of endotoxin molecules (Bergstrand et al., 2006),
otentially affecting its activity and requiring consideration during
reparation. It is also known that varying LPS extraction methods
esult in different LPS products and the exact LPS product of E. coli
55:B5 used for this type of experimental study has not been
onsistently specified. Finally, the equine breed(s) and/or joint
nvestigated may also differ substantially in their biological
esponses.
The aims of this study were: (1) to determine the dose of LPS in
U (derived from E. coli O55:B5 using standardised laboratory
reparation) required to induce mild to moderate lameness
ollowing middle carpal joint injection in Standardbred horses
hat is inhibited by pre-treatment with anti-inflammatory; and (2)
o quantitate the induced lameness over time, with and without
nti-inflammatory pre-treatment.
aterials and methods
The study was approved by the ethical committee of the Faculty of Veterinary
edicine of Ghent University (Approval number, 2015/52; Approval date, 11 June
015).
tudy design and timing
The first part of the study (‘baseline trial’) was based on a rule-based dose-
the same dose of LPS, until a total sample size of eight horses was reached. The
sample size was calculated based on results of a previous study (Van de Water et al.,
2017) with a statistical significance of 0.05 and power of 0.8.
Lameness was evaluated subjectively by two experienced clinicians, and
objectively by an inertial sensor system, every 2 h during the first 12 PIH, every 4 h
during the next 12 PIH, and every 12 h during the last 24 PIH. Based on the results of
de Grauw et al. (2009b), which served as a basis for the present study, the horses
were also subjected to pressure plate analysis at PIH 0, 8, and 24.
Immediately prior to LPS-injection (PIH 0) and at PIH 8, 24 and 48, synovial fluid
was sampled and analysed for total protein, total nucleated cell count and
prostaglandin E2 (PGE2) concentration (de Grauw et al., 2009a,b). At the same time
points, jugular venous blood samples were collected for hematology. In addition,
the horses were under constant veterinary surveillance, with assessment of clinical
parameters including respiratory rate, heart rate, rectal temperature, appetite, fecal
output, signs of colic and other discomfort, although this was not quantified using a
published pain scale.
Following a wash-out period of 2 months, the determined LPS-dose of the
baseline trial was injected into the same eight horses, which had now received 4
days of non-steroidal anti-inflammatory treatment with meloxicam (0.6 mg/kg PO
SID; Metacam, Boehringer Ingelheim) prior to LPS-injection (‘meloxicam trial’), as
described previously by De Grauw et al. (2009a). This medication was continued
during the test period. Subjective and objective lameness assessments, along with
synovial fluid and jugular venous blood sampling were performed as described
above.
Since prior work has demonstrated the ability of meloxicam to significantly
downregulate the inflammatory response to LPS (de Grauw et al., 2009a,b), this
non-steroidal anti-inflammatory (NSAID) was used to test the usability of the
revised LPS model for the future evaluation of substances with a claimed preventive
anti-inflammatory effect. Due to the short-acting inflammatory effect of the
injected LPS, the authors believe that this model is especially useful when
evaluating the preventive rather than curative effects of a wide range of anti-
inflammatory treatments, such as nutritional supplements, even though the model
has already been used successfully in numerous curative treatment trials (Santos
et al., 2009; Van Loon et al., 2010, 2013; Carregaro et al., 2014). Therefore, pre-
treatment with meloxicam was preferred over curative treatment in the present
study.
Throughout the study, humane endpoints were based on lameness and
systemic signs of inflammation. In cases of severe lameness (>4/5 on a scale from
zero [sound] to five [non-weightbearing lameness]), or in cases where any severe
systemic clinical signs were observed, such as fever, tachycardia, tachypnea,
abdominal discomfort, diarrhea or anorexia, withdrawal from the experiment and
provision of rescue medication (NSAID) and further appropriate veterinary care
would have been provided.
Horses
Eight healthy and clinically sound French Standardbred horses were used (mean
 SD age 4  0.5 years; body mass 470  24 kg). Horses with a known history of
musculoskeletal problems were excluded. All horses underwent routine farriery
and were given time to adjust to the research environment, one week prior to each
trial date. During the study period, all horses were individually housed under
identical circumstances and received a standard ration of hay and concentrate feed.
Lameness evaluation
Lameness was evaluated subjectively (routine visual examination) and
objectively (inertial-sensor system and pressure plate) at trot, at the time-points
indicated above. Routine visual examination was performed at trot on a straight line
on a hard surface, by two experienced clinicians, giving a consensus score from 0
(sound) to 5 (non-weightbearing lameness).
Pressure plate (PP) measurements were performed using a dynamically
calibrated pressure plate (Footscan 3D 2 m, RSscan International) mounted on top of
a force plate (BP4602070RS-2K, AMTI). Analysis was performed as described by
Oosterlinck et al. (2012). The following variables were calculated: (1) peak vertical
force (PVF, N/kg); (2) vertical impulse (VI, Ns/kg); (3) stance time (ST, ms). For each
set of five measurements, all left for (LF) and right fore (RF) measurements were
averaged, and subsequently, PVF, VI and ST ratios between both forelimbs were
calculated as -
%RF = RF/(LF + RF)  100
Using this approach, a value of 50 indicated a perfect symmetry between left
and right, whereas a value higher or lower than 50 indicated relatively higher2 See: Equinosis Q system. https://equinosis.com/veterinarians/learn-more/
(Accessed 25 January, 2021).scalation study (Le Tourneau et al., 2009). A post-hoc analysis of LPS enzymatic
ctivity in the stock solution used in the previous study (Van de Water et al., 2017),
evealed that the middle carpal joints had been injected with approximately 5 EU
PS. Therefore, the present study started with a dose of 10 EU. In cohorts of two
orses, this starting dose was injected into the right middle carpal joint and was
creased or decreased in subsequent cohorts if lameness was either too mild to be
etectable or too severe (>4/5), respectively. When the desired degree of lameness
as obtained, additional cohorts of two horses were injected and evaluated with2
loading of the right or left limb, respectively.
Inertial sensor system (ISS) measurements were performed using the Equinosis
Q system (Equinosis)2 at trot in a straight line on a hard surface, with a sensor
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manufacturer. At least 25 strides were analysed with dedicated software (Lameness
Locator 2014 v.2, Equinosis3). Mean forelimb asymmetry was expressed as the
vector sum (VS, mm) of the difference in minimal and maximal head height
between the right and left forelimb during a stride, with a threshold of 8.5 mm for
distinguishing between sound and lame horses (Keegan et al., 2011). In the present
study, a positive value was used for RF lameness, and a negative value for LF
lameness.
Preparation of LPS
The initial stock solution of LPS from E. coli O55:B5 (L5418, Sigma Aldrich; lot
045M4029V) had a concentration of 3000 EU/mL, as quantified using a recombinant
factor C assay (EndoZyme II assay, Hyglos). For every cohort of two horses, an LPS-
solution containing an appropriate dose of LPS (starting with 10 EU/mL for the first
cohort) was prepared, no greater than 1 h prior to injection to ensure stability of the
dilution. Before dilution, the stock solution was vortexed for 10 min at a speed of
1500 rpm to break down endotoxin micelles and achieve a homogenous solution.
Subsequently, the solution was diluted in sterile isotonic saline with micropipettes
under laminar flow and on ice. Between every consecutive dilution step, the
solution was vortexed for 2 min at 1500 rpm. All LPS solutions were stored in glass
vials at 4 C. Immediately before injection, the final solution was vortexed again for
2 min.
Sampling and sample analysis
Following sedation with detomidine (Detogesic, Vetcare) and butorphanol
(Torbugesic, Zoetis), both at a maximal dose of 10 mg/kg IV, synovial fluid samples
(3.5 mL) were collected by aseptic arthrocentesis of the right middle carpal joint
using a 21G 4 cm needle. Samples were immediately divided into two sterile
containers; 1 mL was collected into an EDTA-coated tube and the remaining fluid
was collected in a plain tube. Samples were immediately stored at 4 C and analysed
(EDTA) or processed (plain tube) within 1 h following collection. The EDTA-sample
was analysed for total nucleated cell count (TNCC, 103 cells/mL) with a hematology
analyser (Scil Vet abc Plus+, Scil Animal Care Company; Van de Water et al., 2016)
and total protein (TP, g/L) by spectrometry. The plain tubes were centrifuged at 600
 g for 20 min and the supernatant was divided in aliquots of 500 mL, which were
immediately stored at 80 C within 2 h following sample collection, for
subsequent PGE2-analysis. PGE2 was determined by HPLC-MS/MS analysis on an
HPLC system (PerkinElmer LC200, Perkin Elmer) coupled to an electrospray
ionisation linear ion trap quadrupole mass spectrometer (4000 Q TRAP, Applied
Biosystems). The instrument was operated in negative MRM mode. For extraction,
0.1 M sodium acetate buffer (pH 5) and ethyl acetate were added to 100 mL of
sample. The organic phase was then separated during two consecutive freeze cycles.
After vacuum centrifuging, the residue was dissolved in methanol and measured.
All samples were normalised to an internal standard (16,16-dimethyl PGF2α) and
PGE2 concentrations (pg/mL) were calculated from a standard curve of known
concentrations.
Within the context of safety assessment of LPS, blood samples were taken from
the left jugular vein with a 21 G, 4 cm needle in EDTA-coated vacutainers. Samples
were immediately refrigerated at 4 C, and within 1 h after collection subjected to
hematologic analysis with a hematology analyser (scil Vet abc Plus+, Scil Animal
Care Company).
Statistical analysis
Statistical analysis was performed with SAS version 9.4. Global significance was
set at 5%. A mixed model with horse as random effect, and time, treatment and their
interaction as categorical fixed effects was performed. The treatment effect was also
tested at different time points separately for TNCC and TP at PIH 0, 8, 24 and 48, for %
RF(PVF) and %RF(ST) at PIH 0, 8 and 24 and for VS at PIH 0, 2, 4, 6 and 8, using the
Bonferroni correction for multiple comparisons. As PGE2 and %RF(VI) data
presented significant departures from a normal distribution, that could not be
resolved after logarithmic transformation, a Wilcoxon rank sum test was used
and the treatment was tested at the different time points using the Bonferroni
correction for multiple comparisons.
Results
Lameness evaluation
In all cohorts, the initial dose of 10 EU induced lameness within
sensor system data for PIH 0, 2, 4, 6 and 8 are presented in Tables 1
and 2 respectively. Apart from one horse, the baseline trial
lameness peaked at PIH 4 with a median clinical lameness score of
3 (interquartile range 3–3) and a mean vector sum of 38.7  20
mm. Six horses presented a maximal lameness grade of 2–3/5
(mean  SD VS 36.8  8.5 mm), with one horse showing a peak
lameness of grade 4/5 (VS 78.8 mm). In the final horse, lameness
had already peaked at PIH 2 and only reached grade 1/5 (VS 15.6
mm). In all horses, lameness declined rapidly after the peak and
returned to baseline levels by PIH 48 (Fig.1). In the meloxicam trial,
LPS injection could not provoke any relevant or significant change
in locomotor symmetry.
Pressure plate data are presented in Table 3. At PIH 0, no
significant differences were observed between both trials. VS was
significantly higher in the baseline trial at PIH 2 and 4 (P = 0.004
and P < 0.0001, respectively), compared to the meloxicam trial. For
pressure plate variables (%RF of PVF, VI and ST), no significant
changes were observed following LPS injection, and no significant
differences between either trial could be observed at any time
point.
Table 1
Clinical lameness scores at post-injection hour (PIH) 0, 2, 4, 6 and 8 for both trials
(baseline and meloxicam), presented as median (interquartile range).
PIH Clinical scores
Baseline Meloxicam
0 0.5 (0–1) 0 (0–1)
2 1.5 (1–2) 0.5 (0–1)
4 3.0 (3–3) 0.0 (0–1)
6 2.0 (1.8–2.3) 0.5 (0–1)
8 2.0 (2–3) 0.5 (0–1)
Table 2
Vector sum (VS, in mm) data of the inertial sensor system (Equinosis Q with
Lameness Locator software3) measured at post-injection hour (PIH) 0, 2, 4, 6 and 8
for both trials (baseline and meloxicam), presented as mean  standard deviation.
PIH VS (mm)
Baseline Meloxicam
0 6.1  11.1 9.7  5.3
2 19.5  11.2a 2.2  13.6a
4 38.7  20.0a 10.4  10.4a
6 20.6  11.3 7.3  11.6
8 23.5  10.6 10.8  5.3
a α < 0.05 within time points.the predetermined range, obviating the need for further dose
adjustments. Median clinical lameness scores and mean inertial3 See: The Equinosis Q with Lameness Locator. https://equinosis.com (Accessed
25 January, 2021).
Fig. 1. Mean  standard deviation vector sum (mm) measured with the inertial
sensor system (Equinosis Q with Lameness Locator software3) after lipopolysac-
charide (LPS) injection, showing the lameness pattern for the baseline trial (red)
compared to the meloxicam trial (green). Within time points, statistically
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All synovial fluid data are presented in Table 4. At PIH 0, no
ignificant differences could be observed between the baseline
rial and the meloxicam trial for any synovial fluid parameter. After
PS injection, there was a significant increase in TNCC and TP in
oth trials (P < 0.0001; Fig. 2a, b), whereas PGE2 increased
ignificantly in the baseline trial but not in the meloxicam trial
P < 0.0001; Fig. 3). TNCC and TP did not differ significantly
etween either trial at any time point. However PGE2 was
ignificantly higher at PIH 8 (P = 0.021) and 24 (P = 0.030) in
he baseline trial compared with the meloxicam trial.
ossible systemic effects of LPS injection
Respiratory rate, heart rate, rectal temperature and hematology
arameters remained within normal limits at every time point.
Discussion
The present study revealed that injection of 10 EU of LPS of E.
coli O55:B5 in the middle carpal joint of Standardbred horses
consistently induces synovitis and lameness. The lameness grade
was in agreement with our predefined criteria. As it generally
concerned a moderate and transient lameness and synovitis, it
seemed acceptable in terms of animal welfare, although the latter
certainly comprises more than only lameness grade, and further
measures to assess this should be included in the future.
Due to the first LPS-dose being suitable, no further doses were
tested and therefore it is unknown whether a lower or higher dose
could also have produced a suitable degree of lameness. The
induced lameness in the present study was reasonably consistent
at the moment of peak lameness, but with one horse being grade
4/5 and one horse being only grade 1/5 lame, it seems reasonable to
presume that a higher or lower LPS dose would have resulted in
able 3
ressure plate variables (peak vertical force [PVF], vertical impulse [VI], and stance time [ST]) at post-injection hour (PIH) 0, 8 and 24 for both trials (baseline and meloxicam),
resented as the ratio between the left forelimb (LF) and right forelimb (RF), calculated as – %RF = RF/(LF + RF)  100%. Within time points, no statistically significant
ifferences (α < 0.05) between trials were observed.
PIH %RF of PVFa %RF of VIb %RF of STa
Baseline Meloxicam Baseline Meloxicam Baseline Meloxicam
0 49.42  1.69 48.69  3.31 50.12 (48.3151.42) 49.72 (47.5950.50) 50.31  1.09 49.70  1.28
8 47.94  2.39 48.73  3.47 49.15 (48.1349.58) 48.68 (48.0550.77) 50.05  1.16 50.14  1.19
24 49.42  2.20 49.37  3.27 49.23 (48.2250.07) 49.49 (48.1351.24) 49.92  1.06 50.48  0.69
a Normally distributed data shown as mean  standard deviation.
b Non-normally distributed data shown as median (interquartile range).
able 4
ynovial fluid total nucleated cell counts (TNCC, 109/L), total protein (TP, g/L) and concentration of prostaglandin E2 (PGE2, pg/mL) at post-injection hour (PIH) 0, 8, 24 and 48
r both trials (baseline and meloxicam).
PIH TNCC (109/L)a TP (g /L)a PGE2 (pg/mL)b
Baseline Meloxicam Baseline Meloxicam Baseline Meloxicam
0 0.25  0.16 0.24  0.11 18.0  3.38 17.3  2.12 132.9 (98.3177.9) 96.35 (70.9115.1)
8 126.6  21.8 143.7  21.9 51.5  6.7 56.8  4.3 8742.6 (4892.515353.8)c 620.5 (503.11090.8)c
24 47.4  17.6 47.1  13.2 50.3  7.1 54.3  3.9 1318.2 (894.01692.5)c 401.4 (263.4636.8)c
48 6.25  2.82 7.35  2.5 28.5  2.6 32.0  4.7 366.5 (299.8432.4) 202.4 (184.8264.8)
a Normally distributed data shown as mean  standard deviation.
b Non-normally distributed data shown as median (interquartile range).
c α < 0.05 within time points (α < 0.05).ig. 2. Mean  standard deviation synovial fluid total nucleated cell count (TNCC, 109/L; A) and total protein (TP, g/L; B) for the baseline trial (red) and the meloxicam trial
green). Within time points, no significant differences between trials were observed.
4
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animals comprises an inherent degree of biological variability. As
all external influencing factors were maximally limited in the
present study, the remaining variability may be due to an
individual susceptibility to LPS stimulation, thus inherent to the
LPS model.
Pre-treatment with meloxicam was consistent in avoiding an
increase in visual grade and objective (VS) lameness score
following LPS injection. Meloxicam treatment was specifically
initiated 4 days prior to LPS-injection based on previous work of De
Grauw et al. (2009a), as the authors believe that the model is
particularly useful in providing information regarding preventive
effects of treatments (for example nutritional supplements with
presumed anti-inflammatory properties that can be administered
during daily training), due to the very short duration of
inflammation induced by LPS injection. This pre-treatment with
meloxicam was already well-documented and shown to success-
fully inhibit inflammation and lameness response following LPS
injection (De Grauw et al., 2009a), contributing to the statistical
validity of the model.
With the dose of 10 EU LPS, a significant difference between the
baseline and the meloxicam trial was observed for PGE2
concentration in synovial fluid after LPS injection, but not for
TNCC and TP. These findings are consistent with the results of de
Grauw et al. (2009a,b) reporting a sharp reduction in PGE2
concentration when LPS is injected following oral meloxicam
treatment compared to LPS alone, but no significant effect on white
blood cell count, total protein, or percentage of neutrophils. The
question arises as to what extent this increase in synovial fluid
parameters is due to repeated arthrocentesis and/or injection of a
substance into the joint. However, repeated arthrocentesis
reportedly only has a very mild impact on synovial fluid cytology,
of no clinical importance (Sanchez Teran et al., 2012; Rinnovati
et al., 2017). Even though it could affect synovial biomarker levels
confounding assessment of joint disease in clinical cases (Van den
Boom et al., 2004, 2005), in the LPS model this effect is
overshadowed by the effect of LPS (Ross et al., 2012; Lucia et al.,
2013). Injection of sterile Ringers lactate solution or sterile saline
can also induce mild inflammatory responses that are irrelevant in
comparison with the massive response induced by LPS (Gottschalk
et al., 1998; Campebell et al., 2004; Ross et al., 2012; Lucia et al.,
the authors’ knowledge, the present study is the first to evaluate
the course of lameness after LPS injection in detail using a
combination of visual and objective, quantitative analysis. The use
of the inertial sensor system allowed very frequent objective
lameness measurements (with 2 h intervals only), which is unique
in evaluating the LPS model. In contrast to the inertial sensor
system, the pressure plate analysis could not reveal a significant
increase in locomotion asymmetry following LPS injection. During
the design of the present study, pressure plate evaluation was
scheduled at PIH 8 based on de Grauw et al. (2009a,b). The
discrepancy in timing between the lameness peak and pressure
plate analysis may explain why the inertial sensors were able to
detect a lameness (at PIH 2 and 4), in contrast with the pressure
plate and force plate combination. The timing can probably also
explain the lack of observable lameness in our previous study (Van
de Water et al., 2017), in which lameness evaluation was also
performed at PIH 8.
The LPS dose determined in the present study was estimated to
be about twice the dose used in Van de Water et al. (2017). The
present study highlights the importance of the use of endotoxin
units (EU) instead of units of mass, in addition to the correct
handling and preparation of LPS, to allow for direct comparison
between future studies. As the biological activity of LPS can present
important variation within the same mass of endotoxin (Associates
of Cape Cod Inc., 1997), expressing an LPS-dose in units of mass
creates unnecessary variation, which is not the case when using
EU. During the handling of LPS, vortexing is very important to break
down micelle formation within the solution (Bergstrand et al.,
2006) and thus to achieve a homogenous solution for injection. The
fact that in many studies, vortexing has not been routinely
performed, or at least has not been reported, may be a plausible
reason for the large variation between studies. Furthermore,
pertaining to the biological effects of LPS, the question arises
whether dose and timing are related. It cannot be excluded that the
dose of LPS might influence the timing of the lameness peak. For
this reason, it is of utmost importance to evaluate lameness
following LPS injection at short intervals from PIH 2 to 12, in order
to avoid missing the lameness peak.
Future research is required to evaluate the kinetics of synovial
parameters within the LPS model in more detail, including synovial
biomarkers other than PGE2. In this study, the significant differ-
ences between the baseline and meloxicam trial for PGE2 and
inertial sensor data, indicate that this revised LPS model is suitable
for induction and evaluation of middle carpal joint synovitis and
lameness in Standardbred horses. The ability of meloxicam to
decrease the concentration of the inflammatory biomarker PGE2
shows that this model is suitable for testing substances with
presumed anti-inflammatory properties. Since the induced syno-
vitis is short lived, the model may be more suitable for assessing
the preventive effect of test substances, rather than their curative
effect, although it has been extensively used for the latter (Santos
et al., 2009; Van Loon et al., 2010, 2013; Carregaro et al., 2014).
A limitation of the present study is the use of Standardbred
horses, which theoretically may hamper direct comparison with
studies using other breeds, for example the Warmblood horses
used by de Grauw et al. (2009a,b). However, many different breeds
have been used in previous studies, and at least subjectively, no
clear associations have been observed between horse breed and
reaction to intra-articular LPS injection. A second limitation of this
study is that only PGE was used as a biomarker. While PGE is one
Fig. 3. Median  interquartile range of the synovial fluid prostaglandin E2 (PGE2)
concentration for the baseline trial (red) and the meloxicam trial (green). Within
time points, statistically significant differences between trials are indicated with *
(α < 0.05).2013). Therefore, sham-injected joints were not included in the
present study.
The observed lameness peak in the present study at PIH 4 is in
agreement with studies in which lameness evaluation was also
performed at earlier time points than PIH 8 (Van Loon et al., 2010;
Ross et al., 2012; Van Loon et al., 2012; Andreassen et al., 2017). To5
2 2
of the best-known and widely accepted inflammatory biomarkers
in synovial fluid, it would be interesting to expand the biomarker
panel, as mentioned earlier. A third limitation of this study is the
absence of a cross-over design. This was due to the fact that
the initial part of the study had to be fully completed to determine
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hat humane endpoints were only focused on lameness and
ystemic clinical signs, while measures of animal welfare comprise
ore than those. The absence of systemic clinical signs and severe
ameness alone is not sufficient to state that the model is
cceptable in terms of animal welfare, but at least it is a first
tep. Had severe lameness been induced it would definitely not
ave been acceptable. However, measures of animal welfare other
han lameness should definitely be included in the future. In the
ast decades, several behavioural pain scales have been developed
Gleerup and Lindegaard, 2016). In addition plasma cortisol and
aecal cortisol metabolite measures have been proposed as
ndicators for animal welfare (Pawluski et al., 2017). A final
imitation is that blinded subjective lameness evaluation was not
erformed. This was due to the fact that decisions regarding
ncreasing or decreasing the LPS dose had to be taken immediately.
herefore, and for the continuity of the study, live assessment
as preferred over blinded and randomized video recordings.
oreover, the potential advantage of blinding was considered
egligible because the study focused on objective lameness data
rom an inertial sensor system, of which the statistical analysis was
erformed blinded.
onclusion
This study is the first to standardise the use of the intra-
rticular LPS model for transient synovitis in the horse by using a
niform method of handling LPS solutions (including vortexing)
nd their specification in EUs. Moreover, this study is the first to
eport objective lameness assessments at short intervals following
PS injection from PIH 2, demonstrating a consistent lameness
attern after injection of 10 EU LPS of E. coli O55:B5 in the middle
arpal joint of Standardbred horses, with a mild to moderate
ameness peaking at 4 PIH and returning to baseline within 48 h.
orses receiving meloxicam did not show lameness, illustrating
hat this model is suitable to assess effects of preventive anti-
nflammatory treatment. Significant differences in PGE2 between
oth trials highlight the discriminatory power and, hence, the
sability of the revised model. This study paves the way for
uture efficacy studies using this revised model of acute synovitis
nd lameness to evaluate the preventive effect of different
nti-inflammatory treatments.
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